JPND Launches €23 Million Call For Pathway Analysis Across Neurodegenerative Diseases

The EU Joint Programme – Neurodegenerative Disease Research (JPND) has announced a joint trans-national call for research projects for pathway analysis across neurodegenerative diseases.

PARIS--(BUSINESS WIRE)--Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency. More than 40 million people worldwide are estimated to be living with Alzheimer’s disease and related disorders – the most common class of neurodegenerative disease – and this figure is expected to significantly increase in the coming decades. Yet, with the exception of a few cases, no curative treatment exists, and the basic underlying mechanisms of many neurodegenerative diseases remain poorly understood.

With this in mind, JPND has identified an urgent need for targeted investment to better understand the fundamental links between different diseases. There is already clinical, genetic and biochemical evidence that similar molecular pathways are relevant in different neurodegenerative and other chronic diseases. This call, which follows a similar call successfully launched by JPND in 2013, will see €23 million made available to applicants from 20 countries. It invites proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects to perform network analyses across diseases in order to further elucidate the common underlying mechanisms involved. This combined analysis could lead to a re-definition of clinical phenotypes and new approaches in the treatment of neurodegenerative diseases.

According to Professor Philippe Amouyel, Chair of JPND:

“JPND recognises that a critical step in the path to effective treatments or preventive strategies for neurodegenerative diseases is a deeper understanding of the underlying mechanisms of these diseases. What recent research has made clear is that these conceptual advancements will require greater thinking across traditional clinical boundaries. With this call, some €23 million will be made available to applicants to develop highly specialised cross-border projects that could lead to a better understanding of the biological underpinnings of neurodegenerative disease. Our hope is that these developments will in turn lead to new, outside-the-box diagnostic and therapeutic approaches.”

The neurodegenerative diseases included in the call are Alzheimer’s disease and other dementias, Parkinson’s disease (PD) and PD-related disorders, prion diseases, motor neuron diseases (such as ALS), Huntington’s disease, spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA).

More information about the call is available at: http://www.neurodegenerationresearch.eu/initiatives/pathways-2017/